ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
FTSE 100
8,700.53
-0.31%
Dow Jones
44,303.40
-0.99%
Gold vs US Dollar
2,883.285
0.77%
Brent Oil
74.935
0.42%
Bitcoin
97,071.52
0.60%
Pepperstone
Advertisement
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. ZyVersa Therapeutics Inc (ZVSA)

  7. ZyVersa Therapeutics Inc (ZVSA) News

ZyVersa Therapeutics (ZVSA)

ZyVersa Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ZVSA
DateTimeSourceHeadlineSymbolCompany
24/01/202521:05Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:ZVSAZyVersa Therapeutics Inc
17/01/202521:05Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:ZVSAZyVersa Therapeutics Inc
30/12/202413:30Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:ZVSAZyVersa Therapeutics Inc
27/12/202405:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ZVSAZyVersa Therapeutics Inc
20/12/202422:04Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:ZVSAZyVersa Therapeutics Inc
20/12/202421:15Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:ZVSAZyVersa Therapeutics Inc
18/12/202412:55GlobeNewswire Inc.ZyVersa Therapeutics’ CEO, Stephen C. Glover, to Attend JPM’s Healthcare Conference 2025 in San FranciscoNASDAQ:ZVSAZyVersa Therapeutics Inc
20/11/202412:55GlobeNewswire Inc.ZyVersa Therapeutics Announces Peer-Reviewed Publication Demonstrating That Inflammasome ASC Inhibitor IC 100 Protects Against Stroke-Related Cardiovascular Injury and Dysfunction in Preclinical TrialNASDAQ:ZVSAZyVersa Therapeutics Inc
15/11/202413:35GlobeNewswire Inc.Life Sciences Investor Forum: Presentations Now Available for Online ViewingNASDAQ:ZVSAZyVersa Therapeutics Inc
14/11/202413:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ZVSAZyVersa Therapeutics Inc
14/11/202413:10GlobeNewswire Inc.ZyVersa Therapeutics Reports Third Quarter, 2024 Financial Results and Provides Business UpdateNASDAQ:ZVSAZyVersa Therapeutics Inc
14/11/202413:00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ZVSAZyVersa Therapeutics Inc
06/11/202413:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ZVSAZyVersa Therapeutics Inc
05/11/202412:00GlobeNewswire Inc.ZyVersa Therapeutics Highlights Published Data Demonstrating the Potential of Inflammasome Inhibition to Protect Pancreatic Islet Beta Cells and Attenuate Progression from Obesity to Insulin Resistance and Type 2 DiabetesNASDAQ:ZVSAZyVersa Therapeutics Inc
30/10/202420:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ZVSAZyVersa Therapeutics Inc
29/10/202411:57GlobeNewswire Inc.ZyVersa Therapeutics Highlights Review Article Supporting the Need for Drug Therapies to Treat the Inflammation of Obesity in Addition to Weight Loss DrugsNASDAQ:ZVSAZyVersa Therapeutics Inc
22/10/202411:57GlobeNewswire Inc.ZyVersa Therapeutics Highlights Published Data Demonstrating That Obesity Results in Neuroinflammation Implicated in Development of Neurodegenerative DiseasesNASDAQ:ZVSAZyVersa Therapeutics Inc
17/10/202411:50GlobeNewswire Inc.ZyVersa Therapeutics CEO, Stephen C. Glover, Issues Letter to Shareholders Highlighting Obesity Development Plans for Inflammasome ASC Inhibitor IC 100 Over the Next Nine MonthsNASDAQ:ZVSAZyVersa Therapeutics Inc
15/10/202411:50GlobeNewswire Inc.ZyVersa Therapeutics CEO, Stephen C. Glover, Was a Featured Guest on The Big Biz Show to Discuss Current Trends in the Obesity Drug Market and the Potential Role of Inflammasome InhibitorsNASDAQ:ZVSAZyVersa Therapeutics Inc
07/10/202411:55GlobeNewswire Inc.ZyVersa Therapeutics Forms New Scientific Advisory Board to Support Development of Inflammasome ASC Inhibitor IC 100 for Obesity with Metabolic ComplicationsNASDAQ:ZVSAZyVersa Therapeutics Inc
16/09/202421:30Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ZVSAZyVersa Therapeutics Inc
16/09/202421:29Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ZVSAZyVersa Therapeutics Inc
10/09/202411:25Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:ZVSAZyVersa Therapeutics Inc
10/09/202411:22Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:ZVSAZyVersa Therapeutics Inc
10/09/202404:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ZVSAZyVersa Therapeutics Inc
10/09/202404:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ZVSAZyVersa Therapeutics Inc
09/09/202420:35Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:ZVSAZyVersa Therapeutics Inc
09/09/202420:32Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:ZVSAZyVersa Therapeutics Inc
09/09/202420:30Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:ZVSAZyVersa Therapeutics Inc
03/09/202421:29Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:ZVSAZyVersa Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:ZVSA

Your Recent History

LSE
BARC
Barclays
LSE
GKP
Gulf Keystone Petroleum
LSE
SOLG
Solgold
LSE
VAST
Vast Resources
LSE
ITM
Itm Power
LSE
LGEN
Legal & General
LSE
TGL
Transglobe Energy
LSE
RMR
Rome Resources
LSE
BANK
Fiinu
LSE
MNG
M&g
LSE
ZED
Zenova
LSE
PZC
Pz Cussons
LSE
GEX
Georgina Energy
LSE
AXL
Arrow Exploration
LSE
EDEN
Eden Research
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2025 ADVFN PLC - All Rights Reserved

    Go Ad-Free

    Subscribe to Ad free and enjoy an ad-free experience

    No Ads

    Try Now

    Keep the Ads